Search

Displaying results 4811 - 4820 of 6198 in total
  1. Drug

    Spaglumic acid

    go.drugbank.com/drugs/DB08835
    Investigational

    Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid). In eye drops, spaglumic acid is either a magnesium or sodium salt of N-Acetyl-l-aspartylglutamate....

  2. Drug

    BGT-DTDS

    go.drugbank.com/drugs/DB18664
    Experimental

    BGT-DTDS is an investigational gene therapy comprising an adeno-associated viral vector type 2 (AAV2) encoding the human _SLC6A3_ gene.

  3. Drug

    Trastuzumab botidotin

    go.drugbank.com/drugs/DB17413
    Experimental

    A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable

  4. Drug

    DT-DEC01

    go.drugbank.com/drugs/DB19433
    Experimental

    DT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.

  5. Drug

    Chlorfenson

    go.drugbank.com/drugs/DB05377
    Experimental

    Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.

  6. Drug

    VGA039

    go.drugbank.com/drugs/DB18385
    Investigational

    VGA039 is an IgG4 monoclonal antibody directed against protein S.

  7. Drug

    Aminomethylbenzoic acid

    go.drugbank.com/drugs/DB13244
    Experimental

    Aminomethylbenzoic acid may be useful as an antifibrinolytic agent [A174994].

  8. Drug

    AMG 108

    go.drugbank.com/drugs/DB05545
    Investigational

    AMG 108 was investigated for use as an antirheumatic agent.

  9. Drug

    Desoximetasone

    go.drugbank.com/drugs/DB00547
    Approved

    A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.

  10. Drug

    IR208

    go.drugbank.com/drugs/DB05106
    Investigational

    IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.